|Table of Contents|

Clinicopathological analysis of follicular lymphoma patients with histological transformation

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 08
Page:
1465-1469
Research Field:
Publishing date:

Info

Title:
Clinicopathological analysis of follicular lymphoma patients with histological transformation
Author(s):
HUA Renjie; CHEN Qingjiang; ZHANG Xudong; DUAN Yukai; QIAO Honghan; ZHANG Sijun; ZONG Feiyang
Department of Medical Oncology,the First Affiliated Hospital of Zhengzhou University,Henan Zhengzhou 450052,China.
Keywords:
follicular lymphoma; histological transformation; diffuse large B cell lymphoma; B-lymphoblastic leukemia/lymphoma; prognosis
PACS:
R733.4
DOI:
10.3969/j.issn.1672-4992.2024.08.017
Abstract:
Objective:To investigate the clinical manifestations,histopathological features,therapeutic efficacy and prognosis of follicular lymphoma (FL)patients with histological transformation（HT）.Methods：A total of 26 FL patients with histological transformation treated at our hospital from December 2018 to October 2022 were selected.The clinical features,pathological features,survival status，treatment and efficacy of the patients were collected and analyzed retrospectively.Results:Of the 26 patients with a median age of 57 (43~97) years,25 patients transformed to diffuse large B-cell lymphoma,including 2 low-grade,19 high-grade,and 1 patient transformed to B-lymphoblastic leukemia/lymphoma.Extranodal invasion occurred in 11 cases and bone marrow invasion in 8 cases.There were 17 patients who underwent transformation at the time of initial diagnosis,5 patients achieved CR and 8 patients achieved PR after transformation.9 patients underwent transformation after chemotherapy,4 patients achieved PR after transformation.The ORR of the two groups was 76.5% and 44.4%,there was no statistically difference between the two groups (P=0.194).The median follow-up time of all patients was 22 months,and the median PFS(3~45 months) and OS（5~45）months were not achieved.The 2-year OS and PFS rates were 80.7% and 64.8%,respectively.The results of univariate analysis showed that ECOG score (P=0.040) and Ki-67 (P=0.005) were the factors affecting patients' PFS.Ann Arbor stage (P=0.014) and FLIP-1 score (P=0.008) were the factors that affected patients' OS.Multivariate analysis showed that Ki-67 (P=0.028) was an independent prognostic factor affecting patients PFS.Conclusion:The prognosis of FL patients with histological transformation is poor.Patients with ECOG score≥2 or Ki-67≥70% have poor PFS,and patients with Ann Arbor stage Ⅲ to Ⅳ or FLIP-1 score>2 have poor OS.Ki-67 was an independent prognostic factor affecting patients PFS.

References:

［1］ZHA J,FAN L,YI S,et al.Clinical features and outcomes of 1845 patients with follicular lymphoma:a real-world multicenter experience in China ［J］.J Hematol Oncol,2021,14(1):131.
［2］CASULO C,HEROLD M,HIDDEMANN W,et al.Risk factors for and outcomes of follicular lymphoma histological transformation at first progression in the GALLIUM study ［J］.Clin Lymphoma Myeloma Leuk,2023,23(1):40-48.
［3］PASQUALUCCI L,KHIABANIAN H,FANGAZIO M,et al.Genetics of follicular lymphoma transformation ［J］.Cell Rep,2014,6(1):130-140.
［4］WANG Y,LINK BK,WITZIG TE,et al.Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma ［J］.Blood,2019,134(16):1289-1297.
［5］BARRANCO GI,FERNANDEZ S,ONA R,et al.Branched clonal evolution:nodal follicular lymphoma and primary diffuse large B-cell lymphoma of the central nervous system ［J］.Haematologica,2019,104(7):e326-e329.
［6］FISCHER T,ZING NPC,CHIATTONE CS,et al.Transformed follicular lymphoma ［J］.Ann Hematol,2018,97(1):17-29.
［7］WAGNER-JOHNSTON ND,LINK BK,BYRTEK M,et al.Outcomes of transformed follicular lymphoma in the modern era:a report from the National LymphoCare Study (NLCS) ［J］.Blood,2015,126(7):851-857.
［8］MAESHIMA AM,TANIGUCHI H,HORI Y,et al.Diagnostic utility and prognostic significance of the Ki-67 labeling index in diffuse large B-cell lymphoma transformed from follicular lymphoma:a study of 76 patients ［J］.Pathol Int,2021,71(10):674-681.
［9］MAO X,LI Y,LIU S,et al.Multicolor flow cytometric assessment of Ki-67 expression and its diagnostic value in mature B-cell neoplasms ［J］.Front Oncol,2023,13:1108837.
［10］XUE T,YU BH,YAN WH,et al.Prognostic significance of histologic grade and Ki-67 proliferation index in follicular lymphoma ［J］.Hematol Oncol,2020,38(5):665-672.
［11］MIR F,BARRINGTON SF,BROWN H,et al.Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study ［J］.Blood,2020,135(15):1214-1218.
［12］RAJAMAKI A,KUITUNEN H,SORIGUE M,et al.FDG-PET/CT-guided rebiopsy may find clinically unsuspicious transformation of follicular lymphoma ［J］.Cancer Med,2023,12(1):407-411.
［13］JACOBSEN E.Follicular lymphoma:2023 update on diagnosis and management ［J］.Am J Hematol,2022,97(12):1638-1651.
［14］JANIKOVA A,BORTLICEK Z,CAMPR V,et al.The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era.A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database ［J］.Ann Hematol,2018,97(4):669-678.
［15］GEYER JT,SUBRAMANIYAM S,JIANG Y,et al.Lymphoblastic transformation of follicular lymphoma:a clinicopathologic and molecular analysis of 7 patients ［J］.Hum Pathol,2015,46(2):260-271.

Memo

Memo:
National Natural Science Foundation of China(No.82070210);国家自然科学基金面上项目（编号：82070210）;河南省医学科技攻关重大项目（编号：SBGJ202001008）
Last Update: 1900-01-01